Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Quality of life ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Any adverse events ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Any serious adverse events ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Cytokine release syndrome ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Progression‐free survival ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Complete response ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Adverse events: number of people experiencing adverse events (all cause or COPD‐related), serious adverse events, mortality · COPD
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing adverse events (all… compared with control (low certainty).
1 finding from 1 review
Quality of life: SGRQ total or CCQ · COPD
1 finding from 1 review
Hospital admissions · COPD
It is very uncertain whether single component intervention changes hospital service utilisation: number of people admitted to hospital… compared with control (very low certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · COPD
It is very uncertain whether single component intervention changes exacerbations: number of people experiencing exacerbations compared with control (very low certainty).
1 finding from 1 review
Adverse events: number of people experiencing adverse events (all cause or COPD‐related), serious adverse events, mortality · COPD
It is very uncertain whether single component intervention changes adverse events: number of people experiencing adverse events (all… compared with control (very low certainty).
1 finding from 1 review
Quality of life: SGRQ total, SF CRDQ total, CAT total · COPD
1 finding from 1 review
Hospital admissions · COPD
Multi‐component intervention may leads to lower hospital service utilisation: number of people admitted to hospital… compared with control (low certainty).
1 finding from 1 review
Exacerbations: number of people experiencing moderate or severe exacerbations · COPD
It is very uncertain whether multi‐component intervention changes exacerbations: number of people experiencing moderate or severe… compared with control (very low certainty).
1 finding from 1 review
Intervention not reported
MST vs ECT ‐ symptom severity ‐ HAMD (high = poor; short term) · patients with schizophrenia
1 finding from 1 review
Intervention not reported
MST vs ECT ‐ cognitive function ‐ immediate memory (high = better; short term) · patients with schizophrenia
1 finding from 1 review
Intervention not reported
MST vs ECT ‐ cognitive function ‐ delayed memory (high = better; short term) · patients with schizophrenia
1 finding from 1 review